The Genetics of Serum Cholinesterase 'Deficiency' in Relation to Suxamethonium Apnwea Pharmacogenetics is concerned with inherited differences between individuals in the manner in which they react to particular drugs. On theoretical grounds one may expect that such differences will usually reflect differences in the synthesis of specific enzymes which are in some way involved with the mode of action of the drug or with its metabolism. So far, however, it has been possible in only a few cases to relate an unusual response to a drug to a specific, geneticallydetermined enzyme defect or peculiarity. Nevertheless, one may reasonably anticipate that, with the increasing interest in this kind of phenomenon and with the rapid proliferation of new drugs, many more examples will come to light in the next few years.
The example which I discuss here concerns sensitivity to the drug suxamethonium. This has been extensively studied in recent years, and here I can give only a brief outline of the main findings. However, these will perhaps illustrate the kind of genetical complexities that may underlie a particular form of drug idiosyncrasy.
Suxamethonium (succinyl dicholine) is widely used as a muscle relaxant during surgery and electro-convulsion therapy. Normally its action is quite short because the drug is rapidly hydrolysed into inactive products by an enzyme present in serum. This enzyme is an esterase with a fairly wide substrate specificity which is now officially called acylcholine acyl-hydrolase (International Union of Biochemistry 1961: 3.1.1.8), though it is generally referred to as serum cholinesterase or pseudocholinesterase.
Once the drug became widely used it was found that there were occasional individuals (about 1 in 2,000 in the general population) who were unusually sensitive to its effects. Following a normal dose of the drug such people would develop an extremely prolonged apnoea often lasting an hour or more. It was found that the level of serum cholinesterase activity was generally rather low in these people and it seemed reasonable to suppose that this was the cause of the sensitivity (Bourne et al. 1952 , Evans et al. 1952 , 1953 . Furthermore, it was found that a significant number of the apparently normal relatives of such suxamethonium-sensitive individuals also had in various degrees reduced levels of serum cholinesterase activity (Lehmann & Ryan 1956 , Lehmann & Simmons 1958 , Kaufman et al. 1960 ). This indicated that the peculiarity might be genetically determined and led to the suggestion that suxamethonium-sensitive individuals with low levels of serum cholinesterase were homozygous for an abnormal gene which in heterozygotes resulted in a moderate reduction in the enzyme levels. The three postulated genotypes could not, however, be clearly distinguished one from another on the basis of the serum cholinesterase levels alone since these seemed to be continuously rather than trimodally distributed. An important advance was made when Kalow and his colleagues discovered that the serum cholinesterase present in suxamethonium-sensitive individuals was distinctly unusual in certain of its properties (for review see Kalow 1959 see Kalow , 1962 . For example, using a number of different choline esters as substrate, they found that Michaelis constants determined on the enzyme from suxamethonium-sensitive individuals were significantly greater than the corresponding constants determined in normal controls and that the magnitude of the difference varied from substrate to substrate (Davies et al. 1960) . Theyalso observed significant differences in the effect of certain inhibitors such as physostigmine and dibucaine (Kalow & Davies 1958) . From this and other evidence they were able to conclude that in, suxamethonium-sensitive individuals the serum cholinesterase was atypical in its properties and probably qualitatively different in structure from the serum cholinesterase which occurs in most 503 I other people. Their findings suggested that the 'atypical' enzyme had a reduced apparent affinity for the particular substrates used and it seemed likely that the low activity of the enzyme observed in such individuals was largely due to the reduced catalytic activity of the abnormal enzyme, rather than to a gross reduction in enzyme protein synthesis.
The inhibition studies led to the development of a rather simple test for differentiating the enzymes in routine studies. It involves the determination of the degree of inhibition of serum cholinesterase activity by the inhibitor dibucaine under certain standard conditions (Kalow & Genest 1957) . The percentage inhibition obtained is called the dibucaine number, and has a value of about 20±4 for the 'atypical' enzyme and about 80+±2 for the normal or 'usual' type enzyme. All individuals with dibucaine numbers around 20 will be extremely sensitive to suxamethonium.
When dibucaine number determinations are made on a random sample of the general population, a third group of people can also be clearly identified (Kalow & Staron 1957) . They have dibucaine numbers of about 62±4, and they are said to have the 'intermediate' phenotype. They occur with a frequency of about 1 in 25 in most European populations and they are not found in general to be particularly sensitive to suxamethonium. It is thought that such individuals synthesize both the 'usual' and the 'atypical' forms of serum cholinesterase and do so in roughly equal amounts.
It is interesting to compare the discrimination of the three phenotypes 'usual', 'intermediate' and 'atypical' obtained by dibucaine number determination with that obtained by simple determination of levels of activity as determined by standard methods. On the average, individuals with the 'atypical' phenotype as defined by dibucaine number have lower levels of activity than individuals with the 'usual' phenotype, and 'intermediate' individuals by dibucaine number have intermediate levels of activity (Kalow & Staron 1957 , Harris et al. 1960 ). However, while dibucaine number determinations provide a sharp distinction between the three types, activity determinations do not, since there is considerable overlap of the three distributions. This is perhaps not surprising because, while the dibucaine number is a reflection of the qualitative characteristics of the enzyme and is independent of the quantity of enzyme present, the level of activity depends both on the qualitative characteristics of the enzyme and also on the amount present. Since there are no doubt many extraneous factors which can influence the amount of enzyme protein present in plasma at any given time one would expect the activity determination to be a much more variable and less discriminating characteristic. In practice, one can find occasional individuals with the 'usual' type enzyme with levels of activity as low as those commonly found in the 'atypical' type. However, such individuals are very much less sensitive to suxamethonium and do not generally have a particularly marked apncea.
With the advent of dibucaine number determination detailed genetical studies became possible, and large numbers of families, selected either through suxamethonium-sensitive individuals with the 'atypical' enzyme (Kalow & Staron 1957 , Harris et al. 1960 Occasional families have, however, been found in which the segregation pattern cannot be satisfactorily explained in these simple terms. If all individuals with only the 'atypical' enzyme were homozygous E1aE, , then both their parents and all their children should also carry the gene E:L, and hence be either of the 'intermediate' or 'atypical' phenotypes. However, although this is usually the case, several families have been found in which one of the parents or children of an 'atypical' individual appeared to have only the 'usual' type enzyme (Kalow & Staron 1957 , Harris et al. 1960 , Liddell et al. 1962 . Furthermore, in some of these families the anomalous parent was the mother and so illegitimacy as a general explanation for this phenomenon can be excluded.
These findings require some extension or modification of the hypothesis. They may be most simply accounted for by postulating the segregation in these exceptional families of a rare third allele, E1s, which fails to result in the formation of any functionally active enzyme at all. This has been referred to as the 'silent gene'. If such a gene occurred then one would expect that heterozygotes E1aE1s would form only the 'atypical' enzyme, and heterozygotes EjUEIs only the 'normal' enzyme. In this way the findings in the exceptional families could be accounted for. If this is correct one would also anticipate the occurrence of a genotype EIsEts in which no serum cholinesterase activity could be detected at all.
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Although very rare, several probable examples of this genotype have been recently reported and as might be expected they are extremely sensitive to suxamethonium (Liddell et al. 1962 , Doenicke et al. 1963 ), Hodgkin et al. 1963 . One might also anticipate that EluE1s individuals would on the average have lower levels of activity than EluElu individuals, and similarly ElaEls individuals would have lower levels of activity than ElaEl1 individuals. This indeed appears to be the case, but because there is considerable variation within each of these genotypes it is not possible to identify them unequivocally through activity determinations.
An interesting question is whether the gene Els results in the formation of a structurally abnormal protein devoid of enzyme activity or whether no enzyme protein is formed. Some evidence on this point has been derived from immunological studies. It was found that no cross-reacting material to normal serum cholinesterase could be detected in sera of individuals showing no enzyme activity and thought to be genotypically E,sE,s (Hodgkin et al. 1963) . Thus it may well be that no enzyme protein is synthesized at all, although other explanations of the result still remain possible. A further complication to the genetics of serum cholinesterase was discovered by a somewhat different approach. Some years ago it was observed that the enzyme could be inhibited by low concentrations of fluoride, and rather unexpectedly it was found that the 'usual' and 'atypical' enzymes could be differentiated by this means (Harris & Whittaker 1961) . Under appropriate conditions the 'atypical' enzyme was found to be much less readily inhibited than the 'usual' enzyme. When a large series of sera previously classified into 'usual', 'intermediate' and 'atypical' types by dibucaine number determination were examined using fluoride as inhibitor, it was found that the discrimination into the three phenotypes was, with few exceptions, virtually the same. The exceptions, however, turned out to be of particular interest and it emerged that at least two new phenotypes could be identified by a combination of dibucaine and fluoride inhibition tests.
Family studies (Harris & Whittaker 1962) suggested that there was probably a further allele Elf which determines a third serum cholinesterase variant with properties slightly different from the 'usual' and 'atypical' enzymes previously recognized. The two new phenotypes appeared to represent the genotypes EjuElf and ElaE 9, and recently individuals thought to be homozygous ElfEjf have also been reported (Liddell et al. 1963) .
It is of interest that E1aE,f individuals appear to be rather sensitive to suxamethonium.
If there are indeed four allelic genes which affect serum cholinesterase synthesis in the manner outlined above then ten different genotypes should exist. Their complete identification would require not only inhibition tests with dibucaine and with fluoride but also detailed family studies. Some of these genotypes must of course be extremely rare and not all of them have as yet been identified.
The ten postulated genotypes are listed in Table 1 , and the characteristics of the phenotypes to which they are thought to give rise. A rough indication of their relative frequencies in the general population as far as these can be estimated is also given.
Although for each genotype there is probably a characteristic average level of serum cholinesterase activity as determined by a particular method, the variation is always such that clearcut distinctions between the different types cannot be made on this basis. In fact, if sufficient individuals of the whole array of genotypes could be assembled, a continuous range of variation in enzyme level would no doubt be observed. The average activity values quoted are given relative to the mean value for the genotype EjuEju taken as 1 0. The standard deviations for each genotype are of the order of 0 15-0-20, and since for the less common types the mean value quoted is based on only a few individuals, they must be regarded as only very approximate. These activity values refer to determinations made using benzoylcholine as substrate. It is important to note that the relative values for the different genotypes are different when other substrates are used for the determination.
Markedly prolonged apncea following suxamethonium appears to occur as a regular phenomenon in three of these genotypes (E,aE1a, E1aEjs and ElsE,s). E1aE1f individuals also appear to be rather sensitive to the drug and minor degrees of apncea (lasting perhaps ten to fifteen minutes) may also occur occasionally in some of Although the genotypes associated with severe suxamethonium sensitivity are relatively rare (about 1 in 2,000 of the general population), at least one of the genes concerned (Ela) is relatively common and is present in about 1 in 25 people. Such heterozygous individuals have a demonstrable peculiarity in their serum cholinesterase, but are in other respects perfectly healthy. The peculiarity must therefore be regarded as a not uncommon normal variation. One may well ask why it occurs with such a frequency and what selection pressures have maintained it in the population. As yet we have no real clue about this. It is, however, worth mentioning that it is not the only inherited variation in serum cholinesterase which is relatively common. It has recently been found that up to 10 % of individuals have an extra electrophoretic component of the enzyme which is genetically determined (Harris, Hopkinson, Robson & Whittaker 1963 , Harris, Robson, Glen-Bott & Thornton 1963 ). Its significance is as yet uncertain, and I have not discussed it here because it appears at present to have nothing to do with suxamethonium sensitivity.
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Glucose 6-phosphate Dehydrogenase Deficiency Glucose 6-phosphate dehydrogenase (G6PD) deficiency is a good example of the interaction between a gene and its environment. In the absence of any prejudicial factor the majority of individuals with this enzyme deficiency live unaffected lives, but in the presence of a number of different chemical agents acute red cell destruction will occur. A few patients with almost total deficiency of the enzyme have a severe hemolytic anmmia from birth. Although deficiency of glucose 6-phosphate dehydrogenase may occur in other tissues besides the red cell it does not appear that these tissues suffer any damage.
The function of this enzyme in the red cell appears to be principally to maintain an efficient protective mechanism against the oxidation of heemoglobin. Hemoglobin is am unstable molecule and on its own undergoes slow oxidation to methemoglobin; the presence of many different compounds hastens this process and will actually decompose methemoglobin with the formation of verdo-and choleglobins. A key factor in the red cell which protects hemoglobin against oxidation is the compound glutathione which in the reduced state provides 2 mEq of potential hydrogen ion. The continuous renewal of reduced from oxidized glutathione is accomplished by a metabolic system known as the pentose phosphate pathway and in it G6PD is the initial activator (Fig 1) .
Normally in the red cell 90 % of glucose is converted anaerobically to lactic acid and only 10% is oxidized to pentose phosphates: the limiting factor here is the availability of TPN. However, the formation of oxidized glutathione or of methamoglobin leads to their reaction with TPNH through the appropriate reducing enzyme and to the formation of TPN; the presence of excessive TPN now permits additional oxidation of glucose to pentose, and in this way glutathione and metheemoglobin are reduced (de Loecker & Prankerd 1961). In practice this system of reducing methmmoglobin seems only to operate under adverse environmental conditions, the more usual reduction being accomplished in conjunction with DPN and glycolysis.
In the presence of methylene blue the metabolism of glucose through the pentose phosphate pathway can also be considerably increased and the importance of G6PD in controlling this metabolic route can be shown by comparing glucose oxidation in the red cell in normal and enzyme deficient subjects (Table 1) .
In vitro experiments have demonstrated the protective action of reduced glutathione on haemoglobin. In mixtures containing these compounds the addition of ascorbic acid leads first to the oxidation of glutathione and only subsequently to the oxidation of hxemoglobin and the formation of choleglobin (Jandl et al. 1960) .
In subjects whose red cells are deficient in G6PD similar oxidative end-products of hemo-
